The metastatic behavior of colon cancer cell lines is enhanced by Gal-3 in a carbohydrate-dependent manner through the EGFR/K-Ras–Raf–ERK pathway and is blocked by the EGFR inhibitor cetuximab (Fig. 6a) [179, 180]. Here, EGFR is linked to colonic neoplasm.